Blueprint Medicines Corporation (BPMC) Fundamentals

Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants.
SHARE INFORMATION
Market Cap$ 4,163,648,420
Shares Outstanding59,719,570
Float59,412,712
Percent Float99.49%
Short Interest0.00
Short Percent Float0.0%
Short Interest Ratio0.00
Short Interest Date-
Latest Fiscal Dividend Per Share$ 0.00
Latest Fiscal Revenue$ 180,080,000
Latest Fiscal EPS$ -11.01
Latest Fiscal Date2021-12-31
DIVIDENDS
Dividend (3 Years)$ 0.00
Dividend (5 Years)$ 0.00
Ex Dividend Date-
Dividend Rate$ 0.00
Dividend Yield0.0%
Payment Cash-
HOLDERS
Institutions677
Institutional Holdings Date2022-07-31
Institutional Bought Previous 3 Months12,859,738
Institutional Holdings Percent182.8%
Institutional Sold Previous 3 Months9,090,386
Insider Holdings Date2022-07-31
Insider Bought Previous 3 Months100,669
Insider Holdings Percent1.9
Insider Sold Previous 3 Months57,202
Insider Shares Owned1,157,264
TRADING INFO
52 Week High$ 117.86
52 Week Low$ 43.46
52 Week High Change$ -26.78
21 Day Moving Average$ 57.7086
21 Day Extended Moving Average$ 60.3668
50 Day Moving Average$ 55.5638
50 Day Extended Moving Average$ 57.8632
200 Day Moving Average$ 73.6239
200 Day Extended Moving Average$ 68.7505
10 Day Average Volume869,271
20 Day Average Volume736,225
30 Day Average Volume760,983
50 Day Average Volume902,601
Alpha-0.000764
Beta0.9352
Standard Deviation0.133865
R20.122096
7 Day Price Change$ 5.00
7 Day Percent Change7.73%
21 Day Price Change$ 14.48
21 Day Percent Change26.21%
30 Day Price Change$ 15.91
30 Day Percent Change29.57%
Month to Date Price Change$ 18.66
Month to Date Percent Change36.55%
Quarter to Date Price Change$ 19.21
Quarter to Date Percent Change38.03%
180 Day Price Change$ -12.21
180 Day Percent Change-14.9%
200 Day Price Change$ 0.81
200 Day Percent Change1.18%
Year to Date Price Change$ -37.39
Year to Date Percent Change-34.91%

Blueprint Medicines Corporation (BPMC) Key Ratios

PROFITABILITY
EBIT Margin-302.3%
EBITDA Margin-299.5%
Pre-Tax Profit Margin-400.3%
Profit Margin Count41.08%
Gross Margin90.8%
Profit Margin TOT41.08%
INCOME STATEMENTS
Revenue$ 230,487,000
Revenue Per Share$ 3.8595
Revenue (3 Years)$ 0.00
Revenue (5 Years)$ 0.00
FINANCIAL STRENGTH
Price to Tangible Book5.70
Total Debt To Equity0.10
Int Coverage0.00
Current Ratio6.00
Leverage Ratio1.30
Quick Ratio5.60
Long Term Debt To Capital0.12
VALUATION MEASURES
PE Ratio-6.00
Enterprise Value$ 3,493,379,078
Price to Sales18.0646
Price to Free Cash-6.80
PE High Last 5 Years22.80
Price To Book5.70
Price To Cash Flow16.20
PE Low Last 5 Years-11.40
Price to Tangible Book5.70
MANAGEMENT EFFECTIVENESS
Receivables Turnover8.50
Invoice Turnover0.90
Assets Turnover0.20
Return Assets-54.42
Return on Equity-73.01
Return on Capital-61.82

Blueprint Medicines Corporation (BPMC) Profile

PROFILE INFO
Issue TypeCS
SEC TypeEQS
AuditorErnst & Young LLP
CEOKathryn Haviland
Emplyoees580
Last AuditUQ
CIK0001597264
IndustryBiotechnology
SectorHealthcare
NAICSPharmaceutical Preparation Manufacturing(325412)
CONTACT INFO
Address45 Sidney Street
Cambridge, MA 2139
Websitehttps://www.blueprintmedicines.com
Facsimile-
Telephone+1 617 374-7580
Emailir@blueprintmedicines.com


Your Recent History
NASDAQ
BPMC
Blueprint ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to InvestorsHub
Register Now

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.